About Protein disulfide-isomerase A3
Protein disulfide-isomerase A3 (PDIA3) is a protein
from Homo sapiens identified by UniProt accession
P30101, 505 residues long.
MolForge cross-references it against 0 known binders and
274 disease associations.
Target properties
| Protein name | Protein disulfide-isomerase A3 |
| UniProt accession | P30101 |
| Gene | PDIA3 |
| Organism | Homo sapiens |
| Length | 505 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (274)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.45
- Intellectual disability · score 0.26
- triglyceride measurement · score 0.13
- liver volume · score 0.12
- neoplasm · score 0.11
- cancer · score 0.11
- hepatocellular carcinoma · score 0.10
- lymphocyte count · score 0.10
- oral squamous cell carcinoma · score 0.08
- glioblastoma multiforme · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30101-F1 | alphafold | PREDICTED | 91.34 | — |
Amino-acid sequence (505 residues)
MRLRRLALFP GVALLLAAAR LAAASDVLEL TDDNFESRIS DTGSAGLMLV EFFAPWCGHC KRLAPEYEAA ATRLKGIVPL AKVDCTANTN TCNKYGVSGY PTLKIFRDGE EAGAYDGPRT ADGIVSHLKK QAGPASVPLR TEEEFKKFIS DKDASIVGFF DDSFSEAHSE FLKAASNLRD NYRFAHTNVE SLVNEYDDNG EGIILFRPSH LTNKFEDKTV AYTEQKMTSG KIKKFIQENI FGICPHMTED NKDLIQGKDL LIAYYDVDYE KNAKGSNYWR NRVMMVAKKF LDAGHKLNFA VASRKTFSHE LSDFGLESTA GEIPVVAIRT AKGEKFVMQE EFSRDGKALE RFLQDYFDGN LKRYLKSEPI PESNDGPVKV VVAENFDEIV NNENKDVLIE FYAPWCGHCK NLEPKYKELG EKLSKDPNIV IAKMDATAND VPSPYEVRGF PTIYFSPANK KLNPKKYEGG RELSDFISYL QREATNPPVI QEEKPKKKKK AQEDL
Explore Protein disulfide-isomerase A3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets